

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-26. (Canceled)

27. (New) A method for enhancing the efficacy of a non-polynucleic acid-based cytotoxic or anti-neoplastic agent for a cancer cell, said method comprising administering to a subject hyaluronan and said non-polynucleic acid-based cytotoxic or anti-neoplastic agent.

28. (New) The method according to Claim 27, wherein the hyaluronan has a molecular weight between 400,000 and 900,000 Da.

29. (New) The method according to Claim 28, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

30. (New) The method according to Claim 28, wherein the hyaluronan has a molecular weight of 890,000 Da.

31. (New) The method according to Claim 28, wherein the hyaluronan has a molecular weight of 750,000 Da.

32. (New) The method according to Claim 28, wherein the non-polynucleic acid-based cytotoxic or anti-neoplastic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide or combinations thereof.

33. (New) A method for enhancing the efficacy of a non-polynucleic acid-based cytotoxic or anti-neoplastic agent for a cancer cell, said method comprising administering to a subject a composition consisting essentially of hyaluronan and said non-polynucleic acid-based cytotoxic or anti-neoplastic agent.

34. (New) The method according to Claim 33, wherein the hyaluronan has a molecular weight range between 400,000 and 900,000 Da.

35. (New) The method according to Claim 34, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

36. (New) The method according to Claim 34, wherein the hyaluronan has a molecular weight of 890,000 Da.

37. (New) The method according to Claim 34, wherein the hyaluronan has a molecular weight of 750,000 Da.

38. (New) The method according to Claim 34, wherein the non-polynucleic acid-based cytotoxic or anti-neoplastic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

39. (New) A method for overcoming acquired resistance of cancer cells to a non-polynucleic acid-based cytotoxic or anti-neoplastic agent, said method comprising administering to a subject having said resistant cancer cells a hyaluronan and said non-polynucleic acid-based cytotoxic or anti-neoplastic agent.

40. (New) The method according to Claim 39, wherein the hyaluronan has a molecular weight range between 400,000 and 900,000 Da.

41. (New) The method according to Claim 40, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

42. (New) The method according to Claim 40, wherein the hyaluronan has a molecular weight of 890,000 Da.

43. (New) The method according to Claim 40, wherein the hyaluronan has a molecular weight of 750,000 Da.

44. (New) The method according to Claim 40, wherein the non-polynucleic acid-based cytotoxic or anti-neoplastic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide

45. (New) A pharmaceutical composition consisting essentially of a non-polynucleic acid-based cytotoxic or anti-neoplastic agent and hyaluronan.

46. (New) The pharmaceutical composition of Claim 45, wherein the hyaluronan has a molecular weight range between 400,000 and 900,000 Da.

47. (New) The pharmaceutical composition of Claim 46, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

48. (New) The pharmaceutical composition of Claim 46, wherein the hyaluronan has a molecular weight of 890,000 Da.

49. (New) The pharmaceutical composition of Claim 46, wherein the hyaluronan has a molecular weight of 750,000 Da.

50. (New) The pharmaceutical composition of Claim 46, wherein the non-polynucleic acid-based cytotoxic or anti-neoplastic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

51. (New) A pharmaceutical composition comprising non-polynucleic acid-based cytotoxic or anti-neoplastic agent and hyaluronan having molecular weight of modal molecular weight of 890,000 Da.

52. (New) The pharmaceutical composition of Claim 51, wherein the hyaluronan has molecular weight 890,000 Da.